Jun Qi - Publications

Affiliations: 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States 

172 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE. Author Correction: An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine. PMID 38383796 DOI: 10.1038/s41591-024-02867-1  0.452
2024 Duplaquet L, So K, Ying AW, Li X, Li Y, Qiu X, Li R, Singh S, Wu XS, Liu Q, Qi J, Somerville TDD, Heiling H, Mazzola E, Lee Y, et al. Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. Biorxiv : the Preprint Server For Biology. PMID 38328215 DOI: 10.1101/2024.01.21.576304  0.354
2023 L Vu KA, Kumari K, Liu BH, Gao C, Li F, Tang JP, Maddalo D, Auld DS, Casalena DE, Tian X, Liu M, Bassal MA, Moein S, Iakovleva V, Tan JL, ... Qi J, et al. SALL4B, not targeted by IMiD, is important for SALL4-mediated tumorigenesis. Biorxiv : the Preprint Server For Biology. PMID 37461690 DOI: 10.1101/2023.07.07.548071  0.322
2023 Li M, Yang L, Chan AKN, Pokharel SP, Liu Q, Mattson N, Xu X, Chang WH, Miyashita K, Singh P, Zhang L, Li M, Wu J, Wang J, Chen B, ... Qi J, et al. Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2206584. PMID 37075745 DOI: 10.1002/advs.202206584  0.345
2023 Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, Nibhani R, Wu S, Deng S, Militi S, Dunford J, Philpott M, Fan Y, Fan GC, Liu Q, ... Qi J, et al. BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Biorxiv : the Preprint Server For Biology. PMID 36909530 DOI: 10.1101/2023.03.02.530770  0.309
2022 Sevinç K, Sevinç GG, Cavga AD, Philpott M, Kelekçi S, Can H, Cribbs AP, Yıldız AB, Yılmaz A, Ayar ES, Arabacı DH, Dunford JE, Ata D, Sigua LH, Qi J, et al. BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming. Stem Cell Reports. PMID 36332631 DOI: 10.1016/j.stemcr.2022.10.005  0.325
2022 Guan X, Cheryala N, Karim RM, Chan A, Berndt N, Qi J, Georg GI, Schönbrunn E. Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity. Journal of Medicinal Chemistry. PMID 35867655 DOI: 10.1021/acs.jmedchem.2c00453  0.337
2022 Ding J, Cui XG, Chen HJ, Sun Y, Yu WW, Luo J, Xiao GQ, Chang C, Qi J, Yeh S. Targeting circDGKD Intercepts TKI's Effects on Up-Regulation of Estrogen Receptor β and Vasculogenic Mimicry in Renal Cell Carcinoma. Cancers. 14. PMID 35406411 DOI: 10.3390/cancers14071639  0.313
2022 Zullow HJ, Sankar A, Ingram DR, Samé Guerra DD, D'Avino AR, Collings CK, Lazcano R, Wang WL, Liang Y, Qi J, Lazar AJ, Kadoch C. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. Molecular Cell. PMID 35390276 DOI: 10.1016/j.molcel.2022.03.019  0.327
2022 Wang MY, Liow P, Guzman MIT, Qi J. Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics. Acs Chemical Biology. 17: 744-755. PMID 35363464 DOI: 10.1021/acschembio.2c00062  0.326
2022 Zaiken MC, Flynn R, Paz KG, Rhee SY, Jin S, Mohamed FA, Saha A, Thangavelu G, Park PMC, Hemming ML, Sage PT, Sharpe AH, DuPage M, Bluestone JA, Panoskaltsis-Mortari A, ... ... Qi J, et al. BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. PMID 35226736 DOI: 10.1182/blood.2021014557  0.534
2022 Yang Y, Li L, He H, Shi M, He L, Liang S, Qi J, Chen W. Numb inhibits migration and promotes proliferation of colon cancer cells via RhoA/ROCK signaling pathway repression. Experimental Cell Research. 411: 113004. PMID 34990618 DOI: 10.1016/j.yexcr.2021.113004  0.323
2021 Durbin AD, Wang T, Wimalasena VK, Zimmerman MW, Li D, Dharia NV, Mariani L, Shendy NAM, Nance S, Patel AG, Shao Y, Mundada M, Maxham L, Park PMC, Sigua LH, ... ... Qi J, et al. EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. Cancer Discovery. PMID 34772733 DOI: 10.1158/2159-8290.CD-21-0385  0.353
2021 Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 12: 1736. PMID 34434504 DOI: 10.18632/oncotarget.28051  0.44
2021 Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, ... ... Qi J, et al. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discovery. 2: 370-387. PMID 34258103 DOI: 10.1158/2643-3230.BCD-20-0108  0.347
2021 Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, ... ... Qi J, et al. Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. Cancer Discovery. 2: 370-387. PMID 34233282 DOI: 10.1158/2643-3230.BCD-20-0108  0.368
2021 Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, et al. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia (New York, N.Y.). 23: 624-633. PMID 34107377 DOI: 10.1016/j.neo.2021.05.003  0.559
2021 Muthengi A, Wimalasena VK, Yosief HO, Bikowitz MJ, Sigua LH, Wang T, Li D, Gaieb Z, Dhawan G, Liu S, Erickson J, Amaro RE, Schönbrunn E, Qi J, Zhang W. Development of Dimethylisoxazole-Attached Imidazo[1,2-]pyridines as Potent and Selective CBP/P300 Inhibitors. Journal of Medicinal Chemistry. PMID 33872011 DOI: 10.1021/acs.jmedchem.0c02232  0.302
2021 Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, ... ... Qi J, et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Reports. 34: 108870. PMID 33730585 DOI: 10.1016/j.celrep.2021.108870  0.323
2020 Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debre I, Alexe G, ... ... Qi J, et al. The Folate Cycle Enzyme MTHFR is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discovery. PMID 32826232 DOI: 10.1158/2159-8290.Cd-19-0970  0.408
2020 Duan Q, Huang FL, Li SJ, Chen KZ, Gong L, Qi J, Yang ZH, Yang TL, Li F, Li CQ. BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2. Neuropharmacology. 108255. PMID 32730819 DOI: 10.1016/J.Neuropharm.2020.108255  0.316
2020 Gier RA, Budinich KA, Evitt NH, Cao Z, Freilich ES, Chen Q, Qi J, Lan Y, Kohli RM, Shi J. High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening. Nature Communications. 11: 3455. PMID 32661245 DOI: 10.1038/S41467-020-17209-1  0.344
2020 Li F, Ng WL, Luster TA, Hu H, Sviderskiy VO, Dowling CM, Hollinshead KER, Zouitine P, Zhang H, Huang Q, Ranieri M, Wang W, Fang Z, Chen T, Deng J, ... ... Qi J, et al. Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer. Cancer Research. PMID 32646968 DOI: 10.1158/0008-5472.Can-19-3782  0.781
2020 Antolic A, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Lemieux ME, Conner DA, Lee DY, Qi J, Seidman JG, Bradner JE, Brown JD, Haldar SM, Seidman CE, Burke MA. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. Jci Insight. PMID 32603312 DOI: 10.1172/Jci.Insight.138687  0.547
2020 Qi J, Shi Y. Selective Targeting of Different Bromodomains by Small Molecules. Cancer Cell. 37: 764-766. PMID 32516588 DOI: 10.1016/J.Ccell.2020.05.016  0.369
2020 Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, ... ... Qi J, et al. Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell. PMID 32416067 DOI: 10.1016/J.Molcel.2020.04.027  0.575
2020 Wimalasena VK, Wang T, Sigua LH, Durbin AD, Qi J. Using Chemical Epigenetics to Target Cancer. Molecular Cell. PMID 32407673 DOI: 10.1016/J.Molcel.2020.04.023  0.469
2020 Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, et al. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nature Communications. 11: 2350. PMID 32393766 DOI: 10.1038/S41467-020-16170-3  0.417
2020 Durbin AD, Wimalasena V, Zimmerman MW, Deyao L, Frank ES, Park P, Morita K, Dharia NV, Ross KN, Schonbrunn E, Young RA, Abraham BJ, Stegmaier K, Look AT, Qi J. Abstract PR11: EP300 controls the oncogenic enhancer landscape of high-risk neuroblastoma Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Pr11  0.488
2019 Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatlioglu E, ... ... Qi J, et al. In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma. Cancer Discovery. PMID 31744829 DOI: 10.1158/2159-8290.Cd-19-0780  0.755
2019 Duan Q, Wu P, Liu Z, Xia F, Zhu L, Zheng Z, Yang T, Qi J. BET bromodomain inhibition suppresses adipogenesis in mice. Endocrine. PMID 31691152 DOI: 10.1007/S12020-019-02115-4  0.38
2019 Kong W, Hayashi T, Fiches G, Xu Q, Li M, Que J, Liu S, Zhang W, Qi J, Santoso N, Elledge SJ, Zhu J. Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions. Genomics, Proteomics & Bioinformatics. PMID 31494268 DOI: 10.1016/J.Gpb.2018.12.010  0.318
2019 Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, Enyart BY, Koch KA, Cavasin MA, Alexanian M, Song K, Qi J, Lemieux ME, Srivastava D, Lam MP, et al. Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circulation Research. PMID 31409188 DOI: 10.1161/Circresaha.119.315125  0.382
2019 Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, Wiest O, Yohe ME, Shern JF, Qi J, Khan J. Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nature Communications. 10: 3004. PMID 31285436 DOI: 10.1038/S41467-019-11046-7  0.413
2019 Tatetsu H, Gao C, Armant M, Wang F, Ueno S, Tian X, Federation A, Qi J, Bradner J, Tenen DG, Chai L. Maintenance and enhancement of human PBSC engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology. PMID 31260717 DOI: 10.1016/J.Exphem.2019.06.473  0.549
2019 Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, ... ... Qi J, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications. 10: 2400. PMID 31160565 DOI: 10.1038/S41467-019-10307-9  0.593
2019 Pak E, MacKenzie EL, Zhao X, Pazyra-Murphy MF, Park PMC, Wu L, Shaw DL, Addleson EC, Cayer SS, Lopez BG, Agar NYR, Rubin LL, Qi J, Merk DJ, Segal RA. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma. Neuro-Oncology. PMID 31111916 DOI: 10.1093/Neuonc/Noz089  0.359
2019 Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, Wang X, Liu K, Wang M, Gao J, Li T, Xu M, Silva AS, Lee K, Zhang T, ... ... Qi J, et al. BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell. 35: 752-766.e9. PMID 31085176 DOI: 10.1016/J.Ccell.2019.04.005  0.41
2019 Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. PMID 30962579 DOI: 10.1038/S41375-019-0467-Z  0.434
2019 Song Y, Park P, Wu L, Ray A, Du T, Anderson KC, Qi J, Chauhan D. A Small Molecule-induced Targeted Degradation of Ubiquitin Receptor Rpn13 as a Novel Therapeutic Strategy in Multiple Myeloma Clinical Lymphoma Myeloma and Leukemia. 19: e136. DOI: 10.1016/J.Clml.2019.09.226  0.333
2019 Ohguchi H, Ogiya D, Park P, Hino S, Usuki S, Samur M, Tai Y, Munshi N, Nakao M, Minami T, Qi J, Hideshima T, Anderson KC. KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.09.220  0.318
2018 Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, ... ... Qi J, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 34: 922-938.e7. PMID 30537514 DOI: 10.1016/J.Ccell.2018.11.005  0.443
2018 Zhu X, Holmsen E, Park S, Willingham MC, Qi J, Cheng SY. Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. Oncotarget. 9: 35408-35421. PMID 30459933 DOI: 10.18632/Oncotarget.26253  0.453
2018 Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 7. PMID 30431433 DOI: 10.7554/Elife.41305  0.607
2018 Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, ... Qi J, et al. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 7. PMID 30422115 DOI: 10.7554/Elife.39030  0.466
2018 Rivera-Reyes A, Ye S, E Marino G, Egolf S, E Ciotti G, Chor S, Liu Y, Posimo JM, Park PMC, Pak K, Babichev Y, Sostre-Colón J, Tameire F, Leli NM, Koumenis C, ... ... Qi J, et al. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. Cell Death & Disease. 9: 1108. PMID 30382078 DOI: 10.1038/S41419-018-1142-4  0.373
2018 Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Culter CS, Koreth J, et al. Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease. Blood. PMID 30279226 DOI: 10.1182/Blood-2018-03-839993  0.591
2018 Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA, Wu L, Bradner JE, Qi J, Zhang W. Structure-guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. Journal of Medicinal Chemistry. PMID 30125504 DOI: 10.1021/Acs.Jmedchem.8B00765  0.52
2018 Wang J, Erazo T, Ferguson FM, Buckley DL, Gomez N, Muñoz-Guardiola P, Diéguez-Martínez N, Deng X, Hao M, Massefski W, Fedorov O, Offei-Addo NK, Park PM, Dai L, DiBona A, ... ... Qi J, et al. Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains. Acs Chemical Biology. PMID 30102854 DOI: 10.2210/Pdb6Cd5/Pdb  0.56
2018 Park S, Willingham M, Qi J, Cheng SY. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer. Endocrine-Related Cancer. PMID 29914872 DOI: 10.1530/Erc-18-0071  0.357
2018 Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, ... ... Qi J, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 33: 785-787. PMID 29634952 DOI: 10.1016/j.ccell.2018.03.024  0.452
2018 Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, Leggett AL, Erb MA, Lawlor MA, Souza A, Scott TG, Vittori S, Perry JA, Qi J, Winter GE, et al. The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology. PMID 29581585 DOI: 10.1038/S41589-018-0021-8  0.558
2018 Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, ... ... Qi J, et al. BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica. PMID 29567778 DOI: 10.3324/Haematol.2017.181354  0.348
2018 Bolin S, Borgenvik A, Persson CU, Sundström A, Qi J, Bradner JE, Weiss WA, Cho YJ, Weishaupt H, Swartling FJ. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene. PMID 29511348 DOI: 10.1038/S41388-018-0135-1  0.633
2018 Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, Winter GE, Erb MA, Scott TG, Xu M, Seo HS, Dhe-Paganon S, Kwiatkowski NP, Perry JA, Qi J, et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology. PMID 29507391 DOI: 10.1038/S41589-018-0010-Y  0.575
2018 Ye S, Lawlor MA, Rivera-Reyes A, Egolf S, Chor S, Pak K, Ciotti GE, Lee AC, Marino G, Shah J, Niedzwicki D, Weber K, Park PMC, Alam MZ, Grazioli A, ... ... Qi J, et al. YAP1-mediated suppression of USP31 enhances NF-κB activity to promote sarcomagenesis. Cancer Research. PMID 29490948 DOI: 10.1158/0008-5472.Can-17-4052  0.44
2018 Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Mierlo GV, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, et al. Author response: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma Elife. DOI: 10.7554/Elife.41305.044  0.334
2018 Zeng M, Kwiatkowski NP, Zhang T, Nabet B, Xu M, Liang Y, Quan C, Wang J, Hao M, Palakurthi S, Zhou S, Zeng Q, Kirschmeier PT, Meghani K, Leggett AL, ... Qi J, et al. Author response: Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 Elife. DOI: 10.7554/Elife.39030.023  0.373
2018 Burke MA, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Conner DA, Qi J, Seidman JG, Bradner JE, Brown JD, Haldar SM, Seidman CE. Epigenomic Control of Cardiac Fibrosis by Bet Bromodomain Proteins in Dilated Cardiomyopathy Journal of Cardiac Failure. 24: S2. DOI: 10.1016/J.Cardfail.2018.07.011  0.342
2017 Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, ... ... Qi J, et al. Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell. PMID 29249691 DOI: 10.1016/J.Ccell.2017.11.009  0.572
2017 Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, ... ... Qi J, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell. PMID 29249359 DOI: 10.1016/J.Cell.2017.11.031  0.547
2017 Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. The Journal of Clinical Investigation. PMID 29202477 DOI: 10.1172/Jci90793  0.632
2017 Erwin GS, Grieshop MP, Ali A, Qi J, Lawlor M, Kumar D, Ahmad I, McNally A, Teider N, Worringer K, Sivasankaran R, Syed DN, Eguchi A, Ashraf M, Jeffery J, et al. Synthetic transcription elongation factors license transcription across repressive chromatin. Science (New York, N.Y.). PMID 29192133 DOI: 10.1126/Science.Aan6414  0.566
2017 Gullà A, Hideshima T, Bianchi G, Fulciniti M, Samur MK, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Protein arginine methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in multiple myeloma. Leukemia. PMID 29158558 DOI: 10.1038/Leu.2017.334  0.437
2017 Roti G, Qi J, Kitara S, Sanchez-Martin M, Saur Conway A, Varca AC, Su A, Wu L, Kung AL, Ferrando AA, Bradner JE, Stegmaier K. Leukemia-specific delivery of mutant NOTCH1 targeted therapy. The Journal of Experimental Medicine. PMID 29158376 DOI: 10.1182/Blood.V128.22.889.889  0.591
2017 Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 8: 80109-80123. PMID 29113288 DOI: 10.18632/Oncotarget.19019  0.601
2017 Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, ... ... Qi J, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine. PMID 28805820 DOI: 10.1038/Nm.4378  0.585
2017 Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, et al. HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine. 9. PMID 28701475 DOI: 10.1126/Scitranslmed.Aal5272  0.611
2017 Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, et al. Correction to BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. Journal of Medicinal Chemistry. PMID 28696689 DOI: 10.1021/Acs.Jmedchem.7B00943  0.519
2017 Ayoub AM, Hawk LML, Herzig RJ, Jiang J, Wisniewski AJ, Gee CT, Zhao P, Zhu JY, Berndt N, Offei-Addo NK, Scott TG, Qi J, Bradner JE, Ward TR, Schönbrunn E, et al. BET Bromodomain Inhibitors With One-step Synthesis Discovered from Virtual Screen. Journal of Medicinal Chemistry. PMID 28535045 DOI: 10.1021/Acs.Jmedchem.6B01336  0.578
2017 Enomoto K, Zhu X, Park S, Zhao L, Zhu YJ, Willingham MC, Qi J, Copland JA, Meltzer P, Cheng SY. Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. PMID 28368473 DOI: 10.1210/Jc.2016-3771  0.454
2017 Bian B, Bigonnet M, Gayet O, Loncle C, Maignan A, Gilabert M, Moutardier V, Garcia S, Turrini O, Delpero JR, Giovannini M, Grandval P, Gasmi M, Ouaissi M, Secq V, ... ... Qi J, et al. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. Embo Molecular Medicine. PMID 28275007 DOI: 10.15252/Emmm.201606975  0.602
2017 Bolin S, Borgenvik A, Persson C, Sundström A, Qi J, Bradner J, Weiss W, Cho Y, Weishaupt H, Swartling F. PDTM-34. COMBINED BET BROMODOMAIN AND CDK2 INHIBITION IN MYC-DRIVEN MEDULLOBLASTOMA Neuro-Oncology. 19: vi197-vi197. DOI: 10.1093/Neuonc/Nox168.797  0.575
2016 Cappel D, Hall ML, Lenselink EB, Beuming T, Qi J, Bradner J, Sherman W. Relative Binding Free Energy Calculations Applied to Protein Homology Models. Journal of Chemical Information and Modeling. 56: 2388-2400. PMID 28024402 DOI: 10.1021/Acs.Jcim.6B00362  0.48
2016 Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. PMID 27799547 DOI: 10.1073/Pnas.1608067113  0.617
2016 Duan Q, Xiao Y, Liu Z, Mao X, Zhou Z, Liao C, Cai J, Huang F, Liu Z, Zeng J, Xia K, Chang C, Qi J, Chen Z, Huang H, et al. BET bromodomain is a novel regulator of TAZ and its activity. Biochimica Et Biophysica Acta. PMID 27717711 DOI: 10.1016/J.Bbagrm.2016.10.001  0.43
2016 Xie H, Peng C, Huang J, Li BE, Kim W, Smith EC, Fujiwara Y, Qi J, Cheloni G, Das PP, Nguyen M, Li S, Bradner JE, Orkin SH. Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2. Cancer Discovery. PMID 27630126 DOI: 10.1158/2159-8290.Cd-15-1439  0.584
2016 Xiao Y, Liu Z, Liao C, Mao X, Cai J, Xia K, Qi J, Huang H, Yang T, Duan Q. Inhibition of BET bromodomain improves anemia in APC(min) mice. Leukemia & Lymphoma. 1-4. PMID 27545270 DOI: 10.1080/10428194.2016.1219907  0.301
2016 Zhu X, Enomoto K, Zhao L, Zhu YJ, Willingham MC, Meltzer PS, Qi J, Cheng SY. Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27440272 DOI: 10.1158/1078-0432.Ccr-16-0914  0.358
2016 Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, et al. Mechanism, consequences and therapeutic targeting of abnormal IL-15 signaling in cutaneous T-cell lymphoma. Cancer Discovery. PMID 27422033 DOI: 10.1158/2159-8290.Cd-15-1297  0.514
2016 Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discovery. PMID 27312177 DOI: 10.1158/2159-8290.Cd-16-0164  0.569
2016 Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, et al. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Research. PMID 27280396 DOI: 10.1158/0008-5472.Can-15-2949  0.526
2016 Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine. PMID 27135738 DOI: 10.1038/Nm.4092  0.584
2016 Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nature Genetics. PMID 26829750 DOI: 10.1038/Ng.3502  0.579
2016 Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Jin Huh S, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, ... ... Qi J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. PMID 26735014 DOI: 10.1038/Nature16508  0.612
2016 Zurnic I, Hütter S, Lehmann U, Stanke N, Reh J, Kern T, Lindel F, Gerresheim G, Hamann M, Müllers E, Lesbats P, Cherepanov P, Serrao E, Engelman A, Lindemann D, ... ... Qi J, et al. Proceedings of the Frontiers of Retrovirology Conference 2016 Retrovirology. 13. DOI: 10.1186/S12977-016-0294-5  0.464
2016 Chen CD, Delaney C, Xu H, Koche R, Lujambio Goizueta A, Hoshii T, Cusan M, Chabon J, Valerio DG, Kuehn M, Wang X, Cai S, Chu SH, Chen YK, He J, ... ... Qi J, et al. An Epigenetic Regulator Screen Identifies Novel Targets That Sensitize MLL-Rearranged Leukemia to DOT1L Inhibition Blood. 128: 571-571. DOI: 10.1182/Blood.V128.22.571.571  0.629
2016 Gulla A, Hideshima T, Bianchi G, Fulciniti M, Samur MK, Tai Y, Qi J, Harada T, Morelli E, Amodio N, Carrasco RD, Tagliaferri P, Munshi NC, Tassone P, Anderson KC. Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma Blood. 128: 1140-1140. DOI: 10.1182/Blood.V128.22.1140.1140  0.469
2016 Shu S, Lin C, He HH, Witwicki R, Roberts J, Tabassum D, Liang Y, Ekram M, Doherty E, Brown J, Mohammed H, D'Santos C, McKeown M, Ott C, Qi J, et al. Abstract B16: Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B16  0.636
2016 Stahlhut CE, Ambrico AJ, Watrud KE, Cho H, Wang L, Qi J, Cantley LC, Bradner J, Trotman L. Abstract 4165: Myc vs. Akt therapy in RapidCap, a GEM model for metastatic prostate cancer Cancer Research. 76: 4165-4165. DOI: 10.1158/1538-7445.Am2016-4165  0.537
2016 Bolin S, Borgenvik A, Persson C, Rosén G, Sundström A, Qi J, Bradner JE, Weiss WA, Cho Y, Weishaupt H, Swartling FJ. Abstract 2473: Combined BET-bromodomain and CDK2 inhibition in MYC-driven medulloblastoma Cancer Research. 76: 2473-2473. DOI: 10.1158/1538-7445.Am2016-2473  0.494
2015 Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. PMID 26254443 DOI: 10.1182/Blood-2015-04-639542  0.617
2015 Tanaka M, Roberts JM, Qi J, Bradner JE. Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). Pharmaceutical Patent Analyst. 4: 261-84. PMID 26174566 DOI: 10.4155/Ppa.15.16  0.601
2015 Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia. PMID 26148704 DOI: 10.1038/Leu.2015.142  0.526
2015 Hu YJ, Belaghzal H, Hsiao WY, Qi J, Bradner JE, Guertin DA, Sif S, Imbalzano AN. Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucleic Acids Research. PMID 26117538 DOI: 10.1093/Nar/Gkv645  0.556
2015 Garcia PL, Miller AL, Kreitzburg KM, Council LN, Gamblin TL, Christein JD, Heslin MJ, Arnoletti JP, Richardson JH, Chen D, Hanna CA, Cramer SL, Yang ES, Qi J, Bradner JE, et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene. PMID 25961927 DOI: 10.1038/Onc.2015.126  0.582
2015 Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nature Medicine. 21: 335-43. PMID 25822366 DOI: 10.1038/Nm.3832  0.613
2015 Schölz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J, Jensen LJ, Streicher W, McCarthy AR, Westwood NJ, Lain S, Cox J, Matthias P, Mann M, Bradner JE, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nature Biotechnology. 33: 415-23. PMID 25751058 DOI: 10.1038/Nbt.3130  0.612
2015 Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2348-58. PMID 25688158 DOI: 10.1158/1078-0432.CCR-14-1290  0.6
2015 Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. Acs Chemical Biology. 10: 667-74. PMID 25397901 DOI: 10.1021/Cb500796D  0.532
2015 Lee DH, Qi J, Bradner JE, Said JW, Doan NB, Forscher C, Yang H, Koeffler HP. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. International Journal of Cancer. Journal International Du Cancer. 136: 2055-64. PMID 25307878 DOI: 10.1002/Ijc.29269  0.651
2015 Mishra A, Hartlage A, Sullivan L, Grinshpun L, Kwiatkowski S, Qi J, Bradner JE, Porcu P, Caligiuri MA. Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma Blood. 126: 589-589. DOI: 10.1182/Blood.V126.23.589.589  0.588
2015 Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Ulrich B, Weng H, Wang Y, Huang H, Li S, Strong J, et al. Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides Blood. 126: 3784-3784. DOI: 10.1182/Blood.V126.23.3784.3784  0.519
2015 Stahlhut CE, Watrud KE, Ambrico AJ, Cho H, Wang L, Qi J, Cantley LC, Bradner J, Trotman LC. Abstract 2636: Myc vs. Akt therapy in RapidCap, a GEM model for metastatic prostate cancer Cancer Research. 75: 2636-2636. DOI: 10.1158/1538-7445.Am2015-2636  0.535
2015 Sun B, Shah B, Fiskus W, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner JE, Zu Y, Bhalla KN. Abstract 2612: BET-protein bromodomain antagonist-based combinations against ibrutinb-sensitive or resistant human Mantle Cell Lymphoma cells Cancer Research. 75: 2612-2612. DOI: 10.1158/1538-7445.Am2015-2612  0.355
2015 Garcia PL, Miller AL, Kreitzburg K, Gamblin TL, Christein JD, Arnoletti P, Heslin M, Reddy S, Richardson JH, Yang ES, Qi J, Bradner JE, Yoon KJ. Abstract 1779: Bromodomain inhibitor JQ1 inhibits cholangiocarcinoma tumor growth in patient-derived xenograft models Cancer Research. 75: 1779-1779. DOI: 10.1158/1538-7445.Am2015-1779  0.429
2014 Qi J. Bromodomain and extraterminal domain inhibitors (BETi) for cancer therapy: chemical modulation of chromatin structure. Cold Spring Harbor Perspectives in Biology. 6: a018663. PMID 25452384 DOI: 10.1101/cshperspect.a018663  0.356
2014 Chan CT, Qi J, Smith W, Paranol R, Mazitschek R, West N, Reeves R, Chiosis G, Schreiber SL, Bradner JE, Paulmurugan R, Gambhir SS. Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. Cancer Research. 74: 7475-86. PMID 25320008 DOI: 10.1158/0008-5472.Can-14-0197  0.589
2014 McKeown MR, Shaw DL, Fu H, Liu S, Xu X, Marineau JJ, Huang Y, Zhang X, Buckley DL, Kadam A, Zhang Z, Blacklow SC, Qi J, Zhang W, Bradner JE. Biased multicomponent reactions to develop novel bromodomain inhibitors. Journal of Medicinal Chemistry. 57: 9019-27. PMID 25314271 DOI: 10.1021/Jm501120Z  0.579
2014 Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular Cancer Therapeutics. 13: 2315-27. PMID 25053825 DOI: 10.1158/1535-7163.Mct-14-0258  0.604
2014 Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, ... ... Qi J, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine. 20: 732-40. PMID 24973920 DOI: 10.1038/Nm.3613  0.637
2014 Reynolds C, Roderick JE, LaBelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, et al. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 28: 1819-27. PMID 24552990 DOI: 10.1038/Leu.2014.78  0.545
2014 Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 123: 2075-83. PMID 24470592 DOI: 10.1182/Blood-2014-01-547760  0.597
2014 Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, Robinson BD, Castillo-Martin M, Cordon-Cardo C, Trotman LC. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discovery. 4: 318-333. PMID 24444712 DOI: 10.1158/2159-8290.Cd-13-0346  0.523
2014 Liu S, Walker SR, Nelson EA, Cerulli R, Xiang M, Toniolo PA, Qi J, Stone RM, Wadleigh M, Bradner JE, Frank DA. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Molecular Cancer Therapeutics. 13: 1194-205. PMID 24435449 DOI: 10.1158/1535-7163.Mct-13-0341  0.643
2014 Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular Cancer Therapeutics. 13: 1142-54. PMID 24435446 DOI: 10.1158/1535-7163.Mct-13-0770  0.625
2014 Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, Silverman LB, Sallan SE, Gutierrez A, Look AT, Qi J, Bradner JE, Kelliher MA. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells Blood. 123: 1040-1050. PMID 24394663 DOI: 10.1182/Blood-2013-08-522698  0.573
2014 Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Lovén J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RA. Genome-wide localization of small molecules. Nature Biotechnology. 32: 92-6. PMID 24336317 DOI: 10.1038/Nbt.2776  0.519
2014 Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, ... ... Qi J, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 912-25. PMID 24297863 DOI: 10.1158/1078-0432.Ccr-13-2281  0.624
2014 Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, Chen LF. Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA Oncogene. 33: 2395-2404. PMID 23686307 DOI: 10.1038/Onc.2013.179  0.579
2014 Sun B, Fiskus W, Shah B, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner J, Zu Y, Bhalla KN. Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 124: 918-918. DOI: 10.1182/Blood.V124.21.918.918  0.618
2014 Xie H, Peng C, Qi J, Cheloni G, Das P, Huang J, Nguyen M, Li S, Bradner JE, Orkin SH. Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2 Blood. 124: 778-778. DOI: 10.1182/Blood.V124.21.778.778  0.607
2014 Flynn RP, Goodman K, Qi J, Jing D, Panoskaltsis-Mortari A, Yi Z, Dong C, Liu X, MacDonald KPA, Hill GR, Serody JS, Murphy WJ, Luznik L, Maillard I, Koreth J, et al. Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies Blood. 124: 535-535. DOI: 10.1182/Blood.V124.21.535.535  0.619
2014 Yi JS, Federation A, Qi J, Dhe-Paganon S, Hadler M, Xu X, Varca A, St. Pierre R, Armstrong SA, Bradner JE. Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform Blood. 124: 4811-4811. DOI: 10.1182/Blood.V124.21.4811.4811  0.617
2014 Devaraj SGT, Fiskus W, Shah B, Sharma S, Qi J, Sun B, Saha S, Iyer SP, Zu Y, Bradner J, Bhalla KN. Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells Blood. 124: 3534-3534. DOI: 10.1182/Blood.V124.21.3534.3534  0.643
2014 Roti G, Qi J, Su A, Varca A, Aster JC, Bradner JE, Stegmaier K. Selectively Targeting Mutated NOTCH1 with a Folate-Thapsigargin Derivative Blood. 124: 2158-2158. DOI: 10.1182/Blood.V124.21.2158.2158  0.591
2014 Tatetsu H, Wang F, Gao C, Ueno S, Tian X, Armant M, Federation A, Qi J, Bradner JE, Tenen DG, Chai L. SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells Blood. 124: 1566-1566. DOI: 10.1182/Blood.V124.21.1566.1566  0.498
2014 Roderick JE, Tesell J, Gutierrez A, Look T, Qi J, Bradner JE, Kelliher MA. Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Pr02  0.397
2014 Tang Y, Schubert S, Qi J, Nguyen B, Masoud S, Vue N, Balansay B, Yu F, Atwood SX, Whitson RJ, Ponnuswami A, Chen S, Gholamin S, Pamelyn WJ, Monje-Diesseroth M, et al. Abstract B6: Epigenetic regulation of Hedgehog pathway transcriptional output by BET bromodomain proteins Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B6  0.503
2014 Garcia PL, Gamblin T, Christein JD, Arnoletti JP, Heslin MJ, Richardson JH, Qi J, Bradner JE, Yoon KJ. Abstract 4612: JQ1 suppresses tumor growth in tumorgraft models of pancreatic ductal adenocarcinoma Cancer Research. 74: 4612-4612. DOI: 10.1158/1538-7445.Am2014-4612  0.41
2014 Devaraj SGT, Fiskus W, Sharma S, Qi J, Shah B, Schaub LJ, Rodriguez M, Liu K, Iyer SP, Bradner JE, Bhalla KN. Abstract 3686: HEXIM1 induction exerts a mechanistic role and is a biomarker of lethal activity of BRD4 antagonist against human AML cells Cancer Research. 74: 3686-3686. DOI: 10.1158/1538-7445.Am2014-3686  0.479
2014 Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Lovén J, Sigova AA, Smith WB, Lee TI, Bradner JE, Young RA. Abstract 3230: Genome-wide localization of anti-cancer drugs Cancer Research. 74: 3230-3230. DOI: 10.1158/1538-7445.Am2014-3230  0.362
2014 Bid HK, Phelps DA, Xiao L, Baker L, Qi J, Houghton PJ. Abstract 25: Targeting c-Myc in pediatric sarcoma xenografts with the BET bromodomain inhibitor, JQ1, disrupts angiogenesis Cancer Research. 74: 25-25. DOI: 10.1158/1538-7445.Am2014-25  0.48
2014 Rodriguez M, Fiskus W, Sharma S, Qi J, Schaub LJ, Shah B, Devaraj SGT, Liu K, Iyer S, Bradner JE, Bhalla KN. Abstract 1721: BRD4 antagonist-based therapy exerts lethal activity against FLT3 mutation expressing AML cells resistant to FLT3 tyrosine kinase inhibitors Cancer Research. 74: 1721-1721. DOI: 10.1158/1538-7445.Am2014-1721  0.465
2014 Lee DHT, Qi J, Bradner J, Said J, Doan N, Forscher C, Koeffler HP. Abstract 1689: Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma Cancer Research. 74: 1689-1689. DOI: 10.1158/1538-7445.Am2014-1689  0.626
2014 Cho Y, Tang Y, Schubert S, Willardson M, Bandopadhayay P, Bergthold G, Nguyen B, Masoud S, Vue N, Balansay B, Gholamin S, Cheshier SH, Atwood SX, Whitson RJ, Lee A, ... ... Qi J, et al. EPIGENETIC TARGETING OF HEDGEHOG PATHWAY TRANSCRIPTIONAL OUTPUT Neuro-Oncology. 16: iii25-iii25. DOI: 10.1093/Neuonc/Nou208.9  0.647
2013 Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 24: 777-90. PMID 24332044 DOI: 10.1016/J.Ccr.2013.11.003  0.586
2013 Wu X, Qi J, Bradner JE, Xiao G, Chen LF. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling. The Journal of Biological Chemistry. 288: 36094-105. PMID 24189064 DOI: 10.1074/Jbc.M113.485029  0.599
2013 Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6183-92. PMID 24045185 DOI: 10.1158/1078-0432.Ccr-12-3904  0.577
2013 Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, Bradner JE, McKinsey TA. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy Journal of Molecular and Cellular Cardiology. 63: 175-179. PMID 23939492 DOI: 10.1016/J.Yjmcc.2013.07.017  0.542
2013 Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM. BET bromodomains mediate transcriptional pause release in heart failure Cell. 154: 569-582. PMID 23911322 DOI: 10.1016/J.Cell.2013.07.013  0.542
2013 Frumm SM, Fan ZP, Ross KN, Duvall JR, Gupta S, VerPlank L, Suh BC, Holson E, Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J, Roti G, Kung AL, et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chemistry & Biology. 20: 713-25. PMID 23706636 DOI: 10.1016/J.Chembiol.2013.03.020  0.769
2013 Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, Mcdermott U, Benes CH, Kung AL, Weiss WA, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discovery. 3: 309-323. PMID 23430699 DOI: 10.1158/2159-8290.Cd-12-0418  0.641
2013 David Chen C, Sinha AU, Qi J, Deshpande AJ, Zhu N, Koche R, Eng R, Chang J, Hahn WC, Bradner JE, Armstrong SA. Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia Blood. 122: 598-598. DOI: 10.1182/Blood.V122.21.598.598  0.629
2013 Shammas MA, Souliotis VL, Pal J, Qi J, Brown A, Bradner JE, Anderson KC, Munshi NC. Spontaneous DNA Damage and Aberrant Epigenome In Multiple Myeloma Constitute The Path To Disease Genomic Instability Blood. 122: 4884-4884. DOI: 10.1182/Blood.V122.21.4884.4884  0.312
2013 Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Jakkula LU, Rodriguez M, Devaraj S, Padmanabhan Iyer S, Bradner JE, Bhalla KN. BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells Blood. 122: 485-485. DOI: 10.1182/Blood.V122.21.485.485  0.616
2013 Rodriguez M, Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Devaraj S, Iyer SP, Bradner JE, Bhalla KN. Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD Blood. 122: 3821-3821. DOI: 10.1182/Blood.V122.21.3821.3821  0.62
2013 Shammas MA, Qi J, Samur MK, Hideshima T, Dimopoulos MA, Anderson KC, Bradner JE, Munshi N. Inhibition Of H3K27-Methylome As a Novel Therapeutic Strategy In Multiple Myeloma Blood. 122: 3162-3162. DOI: 10.1182/Blood.V122.21.3162.3162  0.486
2013 Chapuy B, Michael M, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun H, Yeda KT, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma Blood. 122: 3021-3021. DOI: 10.1182/Blood.V122.21.3021.3021  0.648
2013 Valenta JA, Fiskus W, Manshouri T, Sharma S, Qi J, Schaub LJ, Shah B, Rodriguez M, Devaraj S, Iyer SP, Verstovsek S, Bradner JE, Bhalla KN. Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells Blood. 122: 2842-2842. DOI: 10.1182/Blood.V122.21.2842.2842  0.639
2013 Mishra A, La Perle KM, Sullivan L, Sams GH, Curphey DP, McConnell K, Qi J, Wong HK, Kulp SK, Fernandez S, Bradner JE, Marcucci G, Chen C, Porcu P, Caligiuri MA. Increased Expression Of IL-15 Promotes Cutaneous T-Cell Lymphomagenesis Via The Upregulation Of Histone Deacetylases: Evidence For Successful Preclinical Targeting Blood. 122: 1826-1826. DOI: 10.1182/Blood.V122.21.1826.1826  0.508
2013 Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, et al. Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Research. 73: 4622-4622. DOI: 10.1158/1538-7445.Am2013-4622  0.496
2013 Xiao L, Phelps DA, Baker LA, Qi J, Bid HK, Houghton PJ. Abstract 2753: Targeting bromodomain and extra-terminal (BET) family member BRD4 for treatment of pediatric sarcomas. Cancer Research. 73: 2753-2753. DOI: 10.1158/1538-7445.Am2013-2753  0.446
2013 Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay EA, Kimmelman AC, Kung AL, Bradner JE, Wong KK. Abstract 1126: Efficacy of BET bromodomain inhibition in Kras-positive non-small cell lung cancer. Cancer Research. 73: 1126-1126. DOI: 10.1158/1538-7445.Am2013-1126  0.43
2013 Shah B, Jakkula L, Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Rodriguez M, Devaraj SGT, Bradner JE, Bhalla KN. Abstract A124: Co-treatment with BRD4 antagonist and histone deacetylase inhibitor is synergistically lethal against Mantle Cell Lymphoma (MCL) cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A124  0.487
2013 Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, et al. Corrigendum: Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors Nature Communications. 4. DOI: 10.1038/Ncomms2845  0.463
2012 Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nature Communications. 3: 1288. PMID 23250418 DOI: 10.1038/Ncomms2304  0.587
2012 Gong C, Liao H, Wang J, Lin Y, Qi J, Qin L, Tian LQ, Guo FJ. LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. Asian Pacific Journal of Cancer Prevention : Apjcp. 13: 3103-7. PMID 22994717  0.304
2012 Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 120: 2843-52. PMID 22904298 DOI: 10.1182/Blood-2012-02-413021  0.602
2012 Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S, Bradner JE. Small-molecule inhibition of BRDT for male contraception. Cell. 150: 673-84. PMID 22901802 DOI: 10.1016/J.Cell.2012.06.045  0.578
2012 Kopp N, Ott CJ, Bird L, Paranal R, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock D. BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia Blood. 120: 672-672. DOI: 10.1182/Blood.V120.21.672.672  0.423
2012 Liu S, Walker S, Nelson E, Cirulli R, Xiang M, Qi J, Bradner JE, Frank D. Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins Blood. 120: 399-399. DOI: 10.1182/Blood.V120.21.399.399  0.643
2011 Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 146: 904-17. PMID 21889194 DOI: 10.1016/J.Cell.2011.08.017  0.634
2011 Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478: 524-8. PMID 21814200 DOI: 10.1038/Nature10334  0.641
2011 Issa GC, Delmore JE, McKeown MR, Lemieux ME, Rahl PB, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Shi J, Chesi M, Schinzel AC, Vakoc CR, Bergsagel P, et al. Inhibition of c-Myc Expression and Function in Hematologic Malignancies Blood. 118: 1409-1409. DOI: 10.1182/Blood.V118.21.1409.1409  0.577
2011 Qi J, Filippakopoulos P, McKeown M, Shaw KL, Smith WB, French CA, Kung AL, Knapp S, Bradner JE. Abstract 2318: BET bromodomain inhibitors for cancer therapy Cancer Research. 71: 2318-2318. DOI: 10.1158/1538-7445.Am2011-2318  0.492
2010 Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, et al. Selective inhibition of BET bromodomains. Nature. 468: 1067-73. PMID 20871596 DOI: 10.1038/Nature09504  0.591
2010 Sharifi N, Qi J, Bane S, Sharma S, Li R, Robey R, Figg WD, Farrar WL, Kingston DG. Survivin is not induced by novel taxanes. Molecular Pharmaceutics. 7: 2216-23. PMID 20863081 DOI: 10.1021/Mp100211K  0.312
2009 Movassaghi M, Tjandra M, Qi J. Total synthesis of (-)-himandrine Journal of the American Chemical Society. 131: 9648-9650. PMID 19555115 DOI: 10.1021/Ja903790Y  0.527
2009 Movassaghi M, Tjandra M, Qi J. Synthesis of (-)-Himandrine Synfacts. 2009: 1305-1305. DOI: 10.1055/S-0029-1218327  0.516
2006 Trullinger TK, Qi J, Roush WR. Studies on the synthesis of quartromicins a(3) and d(3): synthesis of the vertical and horizontal bis-spirotetronate fragments. The Journal of Organic Chemistry. 71: 6915-22. PMID 16930045 DOI: 10.1021/Jo061059C  0.315
2006 Qi J, Roush WR. Synthesis of precursors of the agalacto (exo) fragment of the quartromicins via an auxiliary-controlled exo-selective Diels-Alder reaction. Organic Letters. 8: 2795-8. PMID 16774259 DOI: 10.1021/Ol0609208  0.316
Show low-probability matches.